There is no confirmed UK launch date
A total of 100 subjects were tested and the VAS score is shown as an average of the obtained VAS scores
However, experts in the area generally concur that a combination of data from multiple endpoints is needed to discriminate sensitizing and/or irritant substances in vitro
Regular follow-up is essential for monitoring treatment effectiveness and adjusting the injection schedule if needed
Matsushita K, van der Velde M, Astor BC, et al
Exclusion criteria for both studies were history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders